Hexarelin
Analogue of GHRP-6 but chemically more stable and potent. Acts on cardiac receptors (cardioprotective effect) in addition to the pituitary.
- Highest GH pulse in class
- Increased strength (neural effect)
- Cardioprotection (reduction of cardiac scar tissue)
- Fat burningHighest GH pulse in class
- Fat burning
- Significant increase in prolactin and cortisol.
- Rapid desensitisation (cyclical use required).
- Post-use fatigue. Significant increase in prolactin and cortisol.
- Post-use fatigue.
Hexarelin is the most potent GH secretagogue in its class, with a chemical structure that gives it superior resistance to enzymatic degradation and unique cardioprotective properties.
READ MORE
What it is (in plain language)
- It's the 'heavy artillery' of GH peptides. It produces the highest peak of growth hormone possible through peptide signalling. It also has a direct and beneficial effect on the heart, helping to protect cardiac tissue after episodes of stress or ischaemia.
Why do you appear online so much
- It is much discussed in experimental cardiac rehabilitation protocols and extreme training phases. However, it is known for its 'desensitisation': if used every day without a break, the body quickly stops responding to it, making it a peptide for short, strategic use.
How it is framed today (pragmatic view)
- 1) Evidence: Strong data on myocardial protection and GH release. 2) Objective: Maximum physical recovery and cardiac muscle health. 3) Risk: Rapid saturation of receptors; requires strict 'cycle' protocols to maintain efficacy.
How to use this form
- See the 'Handling Notes' section to understand the rest intervals required between cycles.
- Quick profile (curated by Subject 157)
- Class: Hormonal
- Status: Verified
- Use case: Performance
- Route: Injectable
- Tags: Injectable|GH|Strength
- Half-life: ~55 mins
- Start: Fast
- Duration: ~3-4 hours
- Mechanism (high level)
Analogue of GHRP-6 but chemically more stable and potent. Acts on cardiac receptors (cardioprotective effect) in addition to the pituitary.
- Evidence (what the literature covers)
RESEARCH RANGE (Cardiology, Non-prescriptive):
Studied for heart failure.
Level of Evidence: B.
- Safety and harm-reduction (non-prescriptive)
Risks: Significant increase in Prolactin and Cortisol.
Rapid desensitisation (cyclical use required).
Post-use fatigue.
Interactions: Dopamine agonists (to control prolactin).
- References (anchors)
- Mao, Y. (2004) - Hexarelin and cardiac function - https://doi.org/10.1210/en.2003-1647 | PubMed:15087431
- Kastin, A. J. (2003) - Hexarelin crossing the blood-brain barrier - https://doi.org/10.1124/jpet.103.051623 | PubMed:12904571
Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.
EN 
PT 
FR 
ES 
DE 
IT 
PL